HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

Parse Biosciences introduces workflow for immune repertoire and transcriptome analysis: Seattle Saturday, January 24, 2026, 15:00 Hrs [IST] Parse Biosciences, the leading provider ...

Melanoma, known for its aggressiveness and high mutational burden, presents itself as a prime candidate for neoantigen-targeted immunotherapies. Although ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...

According to Nova One Advisor, the global next-generation sequencing market size is calculated at USD 17.37 billion in 2026 ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

A research team sheds light on the molecular mechanisms behind foxtail millet (Setaria italica L.) inflorescence development, ...

Scientists can peer into cells to get a limited view of their activity using microscopes and other tools. However, cells and ...